Article Sidebar

PDF
Issue: No. 91 (2025)
Section: Article
DOI: 10.58490/ctump.2025i91.3586
Date Published: 25/09/2025
Views 99
Downloads 50
How to Cite
Thach, T. H. T., Le, T. V., Le, H. P., Lam, V. H., Huynh, M. D., Pham, M. C., & Duong, L. T. T. (2025). EVALUATION OF TREATMENT OUTCOMES AND ASSOCIATED FACTORS IN RECURRENT AND METASTATIC EPITHELIAL OVARIAN CANCER WITH CHEMOTHERAPY COMBINED WITH BEVACIZUMAB AT CAN THO ONCOLOGY HOSPITAL IN 2023 - 2025. Cantho Journal of Medicine and Pharmacy, 91, 30-37. https://doi.org/10.58490/ctump.2025i91.3586

EVALUATION OF TREATMENT OUTCOMES AND ASSOCIATED FACTORS IN RECURRENT AND METASTATIC EPITHELIAL OVARIAN CANCER WITH CHEMOTHERAPY COMBINED WITH BEVACIZUMAB AT CAN THO ONCOLOGY HOSPITAL IN 2023 - 2025

Thi Hoai Thuong Thach1, , Thanh Vu Le1, Hoang Phuc Le1, Vinh Hao Lam1, Minh Dong Huynh1, Minh Chien Pham1, Le Tan Truong Duong1
1 Can Tho University of Medicine and Pharmacy

Main Article Content

Abstract

Background: Ovarian cancer is one of the most common gynecologic malignancies worldwide. Despite the standard first-line treatment consisting of cytoreductive surgery followed by platinum-based chemotherapy, approximately 70% of patients experience disease relapse within five years of diagnosis. However, the addition of Bevacizumab, an anti-angiogenic monoclonal antibody, to chemotherapy regimens has demonstrated improved progression-free survival and overall outcomes in patients with recurrent and metastatic ovarian cancer. Therefore, this study aims to evaluate the therapeutic outcomes and identify prognostic factors influencing treatment response. Objectives: To assess the clinical efficacy and treatment outcomes of chemotherapy combined with Bevacizumab in patients with recurrent and metastatic epithelial ovarian cancer and to analyze prognostic factors associated with treatment response at Can Tho Oncology Hospital from 2023 to 2025. Materials and methods: This prospective cohort study included 31 patients with histologically confirmed recurrent and metastatic epithelial ovarian carcinoma. Patients received systemic chemotherapy in combination with Bevacizumab for a minimum of three cycles or until disease progression or treatment intolerance. Treatment response and survival outcomes were evaluated based on radiologic and clinical assessments. Result: The average age of the patients was 56.94 ± 10.34, with the majority having an ECOG PS score <2 (67.7%). The predominant histological types were ovarian serous carcinoma (48.4%) and Endometrioid ovarian carcinoma (41.9%). CA12-5 was elevated in the majority of patients (83.9%). The treatment response rates after 3 and 6 cycles of chemotherapy were 67.7% and 68%, respectively. Some risk factors such as prolonged use of oral contraceptives, not being pregnant, not breastfeeding, and a family history were associated with the disease. Conclusion: The combination treatment with Bevacizumab in recurrent and metastatic ovarian cancer shows improved response rates and disease control. Some clinical factors and medical history may influence the treatment outcomes. 

Keywords

Ovarian cancer, chemotherapy, Bevacizumab

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

References

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal Clinicians. 2024. 74(3), 229-263, doi: 10.3322/caac.21834.
2. Bộ Y Tế. Hướng dẫn chẩn đoán và điều trị một số bệnh ung bướu. Nhà xuất bản Y học Hà Nội. 2022. 364-365.
3. Konstantinopoulos, Matulonis. Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023. 4(9), 1239-1257, doi: 10.1038/s43018-023-00617-9.
4. Bartoletti M, Pelizzari G, Gerratana L, Bortot L, Lombardi D et al. Bevacizumab or PARPInhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. Int J Mol Sci. 2021. 21(11), doi: 10.3390/ijms21113805.
5. Ghosh R, Lahiri D, Ghosh D, Sen K, et al. Bevacizumab in recurrent epithelial ovarian cancer: real-world experience from a tertiary cancer hospital in India. Ecancermedicalscience. 2025. 32(13), 1302-8, doi: 10.3332/ecancer.2025.1897.
6. DiSilvestro P, Banerjee S, Colombo N, Scambia G, et al. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. J Clin Oncol. 2023. 71(2 Suppl), 5249, doi: 10.1200/JCO.22.01549.
7. Aghajanian C, Blank S V, Goff B A, Judson P L, Teneriello M G, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Journal Clinical Oncology. 2012. 30(17), 2039-45. doi: 10.1200/JCO.2012.42.0505.
8. Gadducci A, Landoni F, Maggino T, Sartori E, Zola P, et al. Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. International Journal of Gynecological Cancer. 1997. 7(1), 78-83, doi: 10.1046/j.1525-1438.1997.00424.x.
9. Miller and Rustin. How to follow-up patients with epithelial ovarian cancer. Current Opinion Oncology. 2010. 22(5), 498-502, doi: 10.1097/CCO.0b013e32833ae8b6.
10. Berek J S, Renz M, Kehoe S, Kumar L, Friedlander. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. International Journal of Gynaecology & Obstetrics. 2021. 155(1), 61-85, doi: 10.1002/ijgo.13878.